SCHEMBL6500664

SCHEMBL6500664

CCN(C(=O)OC(C)(C)C)c1ccc(C)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
S1PR1 P21453 1/20 0.40
CYP3A4 P08684 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.39
CHRNA1 P02708 1/20 0.38
CHRNG P07510 1/20 0.38
CHRNB1 P11230 1/20 0.38
CHRNB2 P17787 1/20 0.38
SLC6A2 P23975 1/20 0.38
CHRNB4 P30926 1/20 0.38
SLC6A4 P31645 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CHRND Q07001 1/20 0.38
HPGD P15428 3/20 0.37
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493574 0.83 CYP3A4 (0.37) RAB9ASMN1; SMN2CYP3A4MEN1KMT2A
SCHEMBL6494266 0.81 CHRNA1 (0.43) RAB9ASMN1; SMN2CYP3A4MEN1KMT2A
SCHEMBL21020989 0.81 CYP4F2 (0.49) CYP3A4MEN1KMT2AHPGDALDH1A1
SCHEMBL27556225 0.81 CYP3A4 (0.36) RAB9ASMN1; SMN2CYP3A4MEN1KMT2A
SCHEMBL6501239 0.80 PDK1 (0.41) RAB9ASMN1; SMN2MEN1KMT2ALMNA
SCHEMBL11289899 0.79 SMN1; SMN2 (0.52) RAB9ASMN1; SMN2S1PR1CYP3A4MEN1
SCHEMBL9419174 0.79 SMN1; SMN2 (0.49) RAB9ASMN1; SMN2S1PR1CYP3A4MEN1
SCHEMBL3315175 0.78 TSHR (0.39) RAB9ASMN1; SMN2CYP3A4MEN1KMT2A
SCHEMBL6492682 0.77 CYP3A4 (0.36) RAB9ACYP3A4ALDH1A1TSHRNPC1
SCHEMBL13000991 0.76 RAB9A (0.43) RAB9ASMN1; SMN2S1PR1CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
CN-1335847-A Sulfonamide compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-13 CN disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed
US-4552585-A Herbicidal 2-(aminophenyl)methyl derivatives of 3-isoxazolidinones or 3-oxazinones FMC CORPORATION (US) 1985-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A RAB9A 2833/4885SMN1; SMN2 325/4885S1PR1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.